kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
CDK protein kinase inhibitor PD 0332991 hydrochloride, 5 mg  

CDK protein kinase inhibitor PD 0332991 hydrochloride, 5 mg

6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one hydrochloride

Synonyms: Palbociclib hydrochloride
PD 0332991 hydrochloride is a cyclin-dependent kinase (CDK) protein kinase inhibitor, specifically targeting on CDK4 and CDK6

More details


Availability: within 3 days

130,00 €

PD 0332991 hydrochloride is an orally active cyclin-dependent kinase (CDK) inhibitor, specifically targeting on CDK4 and CDK6 (IC50 values are 11 and 15 nM for CDK4 and CDK6). A potential agent for the treatment of breast cancer; water soluble hydrochloride salt form, ideal for in vivo experiments. Another salt form, PD 0332991 isethionate is also available.

Prime Source Information:
The molecule of PD0332991 contains multiple basic nitrogens, which could form 1 to 4 eq HCl salt of PD0332991 and its accurate salt form has been determined by microanalysis and specified on certificate of analysis (COA) of every batch of our samples.

Chemical formula: C24H29N7O2.2HCl
Molecular weight: 520.45 g/mol
Purity: >99%
Solubility: Soluble in water
Appearance: Yellow solid
CAS Number: 571189-11-2

Manufacturer:  Axon Medchem BV

PLEASE NOTE: This product is designed for research purposes and can only be delivered to academic and business customers.  


RL Sutherland and EA Musgrove. CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease. Breast Cancer Res. 2009, 11(6), 112-113.

RS Finn et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009, 11(5), R77.

D.W. Fry et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 2004, 3, 1427-1438.

Michaud et al (2010) Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res. 70 3228.

Toogood et al (2005) Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J.Med.Chem. 48 2388.

The following products could also be interesting for you: